APTORUM GROUP LTD-CLASS A (APM) Stock Price, Forecast & Analysis

NASDAQ:APM • KYG6096M1226

0.8449 USD
+0.06 (+8.28%)
At close: Mar 2, 2026
0.8006 USD
-0.04 (-5.24%)
After Hours: 3/2/2026, 8:02:31 PM

APM Key Statistics, Chart & Performance

Key Statistics
Market Cap6.88M
Revenue(TTM)N/A
Net Income(TTM)-4.27M
Shares8.14M
Float5.31M
52 Week High4.47
52 Week Low0.65
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.79
PEN/A
Fwd PE0.01
Earnings (Next)04-28
IPO2018-12-18
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
APM short term performance overview.The bars show the price performance of APM in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

APM long term performance overview.The bars show the price performance of APM in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of APM is 0.8449 USD. In the past month the price decreased by -10.76%. In the past year, price decreased by -10.13%.

APTORUM GROUP LTD-CLASS A / APM Daily stock chart

APM Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
APM Full Technical Analysis Report

APM Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to APM. APM has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
APM Full Fundamental Analysis Report

APM Financial Highlights

Over the last trailing twelve months APM reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 13.79% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -26.46%
ROE -20.19%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-156.89%
Sales Q2Q%N/A
EPS 1Y (TTM)13.79%
Revenue 1Y (TTM)-100%
APM financials

APM Forecast & Estimates

For the next year, analysts expect an EPS growth of 8528.57% and a revenue growth -78.44% for APM


Analysts
Analysts80
Price TargetN/A
EPS Next Y8528.57%
Revenue Next Year-78.44%
APM Analyst EstimatesAPM Analyst Ratings

APM Ownership

Ownership
Inst Owners0.09%
Ins Owners2.17%
Short Float %0.06%
Short Ratio0.05
APM Ownership

APM Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC16.13410.174B
AMGN AMGEN INC17.12209.016B
GILD GILEAD SCIENCES INC16.82184.799B
VRTX VERTEX PHARMACEUTICALS INC23.84126.056B
REGN REGENERON PHARMACEUTICALS17.0282.638B
ALNY ALNYLAM PHARMACEUTICALS INC48.5343.982B
INSM INSMED INC N/A31.848B
NTRA NATERA INC N/A28.947B
BIIB BIOGEN INC12.3628.152B
UTHR UNITED THERAPEUTICS CORP17.4421.698B

About APM

Company Profile

APM logo image Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The firm's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.

Company Info

APTORUM GROUP LTD-CLASS A

17 Hanover Square

London W1S 1BN GB

CEO: Ian Huen

Employees: 1

APM Company Website

APM Investor Relations

Phone: 85239537700

APTORUM GROUP LTD-CLASS A / APM FAQ

What does APM do?

Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The firm's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.


What is the stock price of APTORUM GROUP LTD-CLASS A today?

The current stock price of APM is 0.8449 USD. The price increased by 8.28% in the last trading session.


Does APTORUM GROUP LTD-CLASS A pay dividends?

APM does not pay a dividend.


How is the ChartMill rating for APTORUM GROUP LTD-CLASS A?

APM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


On which exchange is APM stock listed?

APM stock is listed on the Nasdaq exchange.


Can you provide the market cap for APTORUM GROUP LTD-CLASS A?

APTORUM GROUP LTD-CLASS A (APM) has a market capitalization of 6.88M USD. This makes APM a Nano Cap stock.


What is the ownership structure of APTORUM GROUP LTD-CLASS A (APM)?

You can find the ownership structure of APTORUM GROUP LTD-CLASS A (APM) on the Ownership tab.